GBC-HpVac is an ambitious biotechnology start-up specializing in the development of novel treatments for allergic diseases based on immunomodulatory proteins produced by the human microbiota. The team at the GBC-HpVac is a small close-knit group of experts in preclinical & clinical development, sales, marketing, legal and finance. The GBC-HpVac will soon start the lead optimization phase of its lead molecule GBC-R1 and is seeking to bolster its team with a project manager to diversify and strengthen the expertise within the group.